SG10201407258RA - Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation - Google Patents

Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Info

Publication number
SG10201407258RA
SG10201407258RA SG10201407258RA SG10201407258RA SG10201407258RA SG 10201407258R A SG10201407258R A SG 10201407258RA SG 10201407258R A SG10201407258R A SG 10201407258RA SG 10201407258R A SG10201407258R A SG 10201407258RA SG 10201407258R A SG10201407258R A SG 10201407258RA
Authority
SG
Singapore
Prior art keywords
phosphodiesterase
inhibitors
cognitive
motor rehabilitation
motor
Prior art date
Application number
SG10201407258RA
Other languages
English (en)
Inventor
Thomas M Hallam
Rusiko Bourtchouladze
Timothy Tully
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of SG10201407258RA publication Critical patent/SG10201407258RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
SG10201407258RA 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation SG10201407258RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80194906P 2006-05-19 2006-05-19

Publications (1)

Publication Number Publication Date
SG10201407258RA true SG10201407258RA (en) 2015-01-29

Family

ID=38617977

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407258RA SG10201407258RA (en) 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
SG2011035813A SG172602A1 (en) 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011035813A SG172602A1 (en) 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Country Status (11)

Country Link
EP (2) EP2377533A3 (cg-RX-API-DMAC10.html)
JP (2) JP2009537568A (cg-RX-API-DMAC10.html)
CN (1) CN101500559B (cg-RX-API-DMAC10.html)
AU (1) AU2007253734B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0711816A2 (cg-RX-API-DMAC10.html)
CA (1) CA2653042C (cg-RX-API-DMAC10.html)
ES (1) ES2412481T3 (cg-RX-API-DMAC10.html)
IL (1) IL195295A (cg-RX-API-DMAC10.html)
MX (1) MX2008014713A (cg-RX-API-DMAC10.html)
SG (2) SG10201407258RA (cg-RX-API-DMAC10.html)
WO (1) WO2007137181A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
BRPI0916228A2 (pt) * 2008-07-18 2015-11-03 Dart Neuroscience Llc métodos e sistemas para avaliação de agentes de memória
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US9727691B2 (en) 2011-09-30 2017-08-08 Tokyo Metropolitan Institute Of Medical Science Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
CA3103781C (en) * 2019-12-23 2023-02-14 Peter Anthony Hall Method and system for assessing cognitive function of an individual

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
FI944549L (fi) 1992-04-02 1994-11-30 Smithkline Beecham Corp Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
AU678158B2 (en) 1992-04-10 1997-05-22 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
EP0781335A1 (en) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
WO2000014083A1 (en) 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
WO2000050402A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
US7947731B2 (en) * 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
JP2004532809A (ja) * 2000-11-02 2004-10-28 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
WO2003032981A1 (en) * 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
AU2003210869A1 (en) * 2002-02-07 2003-09-02 University Of Miami Schwann cell and phosphodiesterase inhibitors based therapy
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
US20090298864A1 (en) * 2005-04-11 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for Treating Mild Cognitive Impairment

Also Published As

Publication number Publication date
WO2007137181A2 (en) 2007-11-29
SG172602A1 (en) 2011-07-28
EP2021001B1 (en) 2012-12-12
CA2653042C (en) 2016-07-05
CN101500559A (zh) 2009-08-05
IL195295A (en) 2015-11-30
ES2412481T3 (es) 2013-07-11
EP2021001A2 (en) 2009-02-11
AU2007253734B2 (en) 2013-07-25
MX2008014713A (es) 2009-04-17
HK1130656A1 (en) 2010-01-08
EP2377533A3 (en) 2012-02-22
CA2653042A1 (en) 2007-11-29
JP2015042667A (ja) 2015-03-05
EP2377533A2 (en) 2011-10-19
CN101500559B (zh) 2014-01-08
WO2007137181A3 (en) 2008-08-07
AU2007253734A1 (en) 2007-11-29
BRPI0711816A2 (pt) 2011-12-13
JP2009537568A (ja) 2009-10-29
IL195295A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
WO2007137181A3 (en) Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
NL301145I1 (cg-RX-API-DMAC10.html)
MX2009002496A (es) Combinaciones que contienen un derivado de 4-acilaminopiridina.
MX2009005787A (es) Metodos para tratar lupus eritematoso sistemico.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EP1786515A4 (en) TREATMENT OF THE VEGETABLE NERVOUS SYSTEM
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
WO2005097825A3 (en) Bmp-7 variants with improved properties
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
WO2007117344A3 (en) Differentiating and/or identifying tissue regions innervated by targeted nerves
WO2007134077A3 (en) 5 ht receptor mediated neurogenesis
PL2426220T3 (pl) Wyznakowane mikroorganizmy i sposoby wyznakowania
TW200722085A (en) Neurotherapeutic azole compounds
WO2008083204A3 (en) Modulation of neurogenesis by melatoninergic ligands
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
IL189202A0 (en) Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
IL184578A0 (en) Method and composition for treating central nervous system disorders
GB2475660A (en) Methods and kits for treating cluster headache disorders
IL190831A0 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
IL180732A0 (en) Method for treating nervous system disorders and conditions
ZA200705502B (en) System and method for diagnosis of brainstem disorders
WO2010111136A9 (en) Aliskiren modulation of neurogenesis
TW200605871A (en) Carboxamido opioid compounds
ZA200700578B (en) Method for treating nervous system disorders and conditions